Anlotinib Plus Chemotherapy for Patients With Advanced Non-small Cell Lung Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Not yet recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Anlotinib
- Docetaxel
- Lung Neoplasms
- Pemetrexed
- S-1
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 75 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03589950
- Collaborators
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Investigators
- Not Provided
Get Well Soon